Afatinib for recurring HER2-positive uterine cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests afatinib, a targeted pill, in people whose uterine serous cancer has a specific HER2 (HER2/neu) tumor marker. It aims to shrink tumors or control the cancer when it keeps coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your uterine serous cancer is confirmed, and it is persistent or has returned
- Your tumor must be HER2-positive by specific lab tests (IHC 2+ or 3+ plus confirmed gene amplification by FISH)
- You must have measurable cancer on scans and at least one clear target spot for tracking response
- Your overall health must be good enough for treatment (ECOG 0 or 1) and your blood counts and organs must meet lab limits
- You must have recovered from recent surgery, radiation, or chemotherapy and not have a serious infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral targeted drugs for people with recurrent low-grade serous ovarian cancer. It aims to see if this therapy works better than standard hormone therapy or chemotherapy options.
This trial is testing an oral drug called azenosertib for a type of uterine cancer that has come back or spread. It aims to see if blocking a DNA repair pathway can shrink tumors or slow their growth.
This trial tests a combination of two targeted drugs (afatinib and palbociclib) for people with advanced esophageal squamous cell carcinoma that has grown after previous treatment. It is designed for those whose cancer cells have too much of a protein called EGFR.
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
This trial tests whether combining afatinib (a targeted pill for EGFR mutations) with chemotherapy can shrink advanced stage III non-small cell lung cancer (NSCLC) enough to make surgery possible. It is for people whose cancer has not been treated yet and has a specific EGFR mutation.
This trial tests two targeted drugs, trastuzumab deruxtecan and afatinib, together for advanced stomach or gastroesophageal junction cancer that has low levels of the HER2 protein. The goal is to see if the combination shrinks tumors or slows cancer growth.
Hear when a new HER2/Neu+ Uterine Serous Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.